Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib food and esomeprazole effect in healthy participants
NCT06378658Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sevabertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bayer. Primary endpoints: Maximum observed concentration at Day 12 and Area under the curve at Day 12. Started Mar 2024; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06378658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378658.